REVELUTION-2 Trial Is Evaluating Cardiovascular Risk With Relugolix Plus Abiraterone Acetate in High-Risk Prostate Cancer
Sagar A. Patel, MD, discusses the REVELUTION-2 trial evaluating cardiovascular safety with hormone therapy in prostate cancer.
source
Reporting by onclive. The original article may no longer be reachable at its published URL.
read at onclive ↗
comments(0)
5-min edit window · permanent after that